Jeffrey J Raizer

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. pmc Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy
    Jeffrey J Raizer
    Neurology Department, Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Neuro Oncol 6:247-52. 2004
  2. pmc A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:95-103. 2010
  3. doi request reprint Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma
    Jeffrey J Raizer
    Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    Cancer 118:3743-8. 2012
  4. doi request reprint Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases
    Priya Kumthekar
    Departments of Neurology, Northwestern University, Chicago, IL 60611, USA
    J Neurooncol 112:247-55. 2013
  5. doi request reprint Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas
    Sean A Grimm
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Neurooncol 110:237-43. 2012
  6. pmc A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:87-94. 2010
  7. doi request reprint A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
    Jeffrey J Raizer
    Department of Neurology, Northwestern University, Chicago, IL, USA
    Cancer 116:5297-305. 2010
  8. pmc Gene-protein correlation in single cells
    Jaclyn J Renfrow
    Northwestern Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Neuro Oncol 13:880-5. 2011
  9. doi request reprint Immunotherapeutic treatment strategies for primary brain tumors
    Sunit Das
    Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 North St Clair Street, Suite 2210, Chicago, IL 60611, USA
    Curr Treat Options Oncol 9:32-40. 2008
  10. ncbi request reprint Chemotherapy in the treatment of malignant gliomas
    Jennifer I Stern
    Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 6:755-67. 2006

Detail Information

Publications31

  1. pmc Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy
    Jeffrey J Raizer
    Neurology Department, Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Neuro Oncol 6:247-52. 2004
    ..This is the recommended dose for phase 2, but myelosuppression after cycle 1 suggests that long-term treatment may be difficult...
  2. pmc A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:95-103. 2010
    ..001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT...
  3. doi request reprint Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma
    Jeffrey J Raizer
    Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    Cancer 118:3743-8. 2012
    ..Because methotrexate is an integral part of PCSNL treatment, the authors assessed the antitumor activity and safety of pemetrexed in recurrent PCNSL...
  4. doi request reprint Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases
    Priya Kumthekar
    Departments of Neurology, Northwestern University, Chicago, IL 60611, USA
    J Neurooncol 112:247-55. 2013
    ..Pemetrexed was tolerated in solid tumor patients with CNS metastases. Limited anti-tumor activity was seen, which might have been due to low CSF concentrations, although some patients displayed prolonged benefit...
  5. doi request reprint Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas
    Sean A Grimm
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Neurooncol 110:237-43. 2012
    ..The MTD of TMZ 75 mg/m(2)/ATO 0.2 mg/kg was safe and well tolerated. A phase II study evaluating the efficacy of this combination is underway...
  6. pmc A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:87-94. 2010
    ..This has important implications for further development of this drug in the treatment of MG as well as the optimal management of patients with other malignancies such as NSCLC who are on enzyme-inducing drugs...
  7. doi request reprint A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
    Jeffrey J Raizer
    Department of Neurology, Northwestern University, Chicago, IL, USA
    Cancer 116:5297-305. 2010
    ..The authors evaluated a 3-week schedule of bevacizumab in patients with recurrent high-grade glioma (HGG)...
  8. pmc Gene-protein correlation in single cells
    Jaclyn J Renfrow
    Northwestern Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Neuro Oncol 13:880-5. 2011
    ..We demonstrate that the fluorescent in situ gene protein assay methodology is capable of resolving gene and protein patterns simultaneously on a cell-by-cell basis...
  9. doi request reprint Immunotherapeutic treatment strategies for primary brain tumors
    Sunit Das
    Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 North St Clair Street, Suite 2210, Chicago, IL 60611, USA
    Curr Treat Options Oncol 9:32-40. 2008
    ..It is with cautious optimism that the authors review the past and discuss the present status of immunotherapy and its role in the management of patients with primary brain tumors...
  10. ncbi request reprint Chemotherapy in the treatment of malignant gliomas
    Jennifer I Stern
    Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 6:755-67. 2006
    ..As treatments for brain tumors evolve, it is likely that optimal therapies will come from combination therapies that incorporate target-specific and chemotherapeutic agents...
  11. ncbi request reprint Surgery for brain metastases
    Sunit Das
    Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Cancer Treat Res 136:75-90. 2007
  12. doi request reprint Low-grade gliomas: management issues
    Isis Duran
    Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Abbott Hall, Department of Neurology, Room 1115, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 7:S15-21. 2007
    ..The optimal management of these tumors remains to be defined and has some controversies associated with it. In this review, we present the data that is available to date and some of the issues that exist in treating these tumors...
  13. ncbi request reprint Chordomas of the craniospinal axis: multimodality surgical, radiation and medical management strategies
    Kenji Muro
    University Feinberg School of Medicine, Department of Neurological Surgery, Northwestern, Robert H Lurie Comprehensive Cancer Center, 676 North St Clair Street, Suite 2210, Chicago, Illinois 60611, USA
    Expert Rev Neurother 7:1295-312. 2007
    ..In this review, the current multimodality treatment strategy for chordomas will be discussed and future directions will be highlighted...
  14. ncbi request reprint Oligodendroglioma of the pineal region. Case report
    Sunit Das
    Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Neurosurg 105:461-4. 2006
    ..Although the spectrum of tumors arising within the region of the pineal gland is broad, to the authors' knowledge this is the first report of an oligodendroglioma occurring in this area...
  15. doi request reprint Metastatic glioblastoma: case presentations and a review of the literature
    Gauri Kalokhe
    Department of Neurology, Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Abbott Hall, Room 1123, Chicago, IL 60611, USA
    J Neurooncol 107:21-7. 2012
    ..Early diagnosis of metastatic disease spread can help to expedite alleviation of patients' discomfort, in an already aggressive disease process...
  16. ncbi request reprint Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas
    Kenji Muro
    Department of Neurology, Northwestern University, Feinberg School of Medicine, Abbott Hall, Suite 1123, 710 N Lake Shore Drive, Chicago, Illinois 60611, USA
    Technol Cancer Res Treat 5:201-13. 2006
    ..This discussion will be followed by a description of agents currently in preclinical and clinical development, many of which are the result of intense ongoing research into the molecular biology of gliomas...
  17. ncbi request reprint Meningiomas
    Sean Grimm
    Jeffrey Raizer, MD Department of Neurology, Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Abbott Hall, Room 1123, Chicago, IL 60611, USA
    Curr Treat Options Neurol 10:315-20. 2008
    ..No agent is optimal, but hydroxyurea is used most often. Newer approaches such as the use of inhibitors of somatostatin receptors or signal transduction pathways are under investigation...
  18. ncbi request reprint HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme
    Jeffrey J Raizer
    Northwestern University, Feinberg School of Medicine, Abbott Hall, Room 1123, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    J Neurooncol 74:77-86. 2005
    ..GBM treatment with HER1/EGFR TKIs alone or combined with other targeted therapies and conventional modalities deserve further investigation and refinement, as does our understanding of their mechanisms of action and the role of genetics...
  19. ncbi request reprint Primary central nervous system lymphoma
    Jennifer I Stern
    Department of Neurology, Feinberg School of Medicine, Northwestern University, 710 North Lake Shore Dr, Chicago, IL 60611, USA
    Expert Rev Neurother 5:S63-70. 2005
    ..Recent investigations include the use of rituximab (immunotherapy) and stem-cell transplantation, as well as regimens without whole-brain radiation therapy in the elderly. The optimal treatment regimen is yet to been determined...
  20. pmc Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features
    Jeffrey J Raizer
    Feinberg School of Medicine, Department of Neurology, Northwestern University, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    Neuro Oncol 10:199-207. 2008
    ..The prognostic factors identified in this retrospective study should be considered when making treatment decisions for patients with BM and used as stratification factors in future clinical trials...
  21. ncbi request reprint Central nervous system cancers: Clinical Practice Guidelines in Oncology
    Steven S Brem
    J Natl Compr Canc Netw 3:644-90. 2005
  22. pmc Survey of treatment recommendations for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 9:314-8. 2007
    ....
  23. ncbi request reprint Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7841-50. 2005
    ....
  24. ncbi request reprint A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    J Neurooncol 87:85-90. 2008
    ..To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors...
  25. pmc A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
    Raja B Khan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 4:39-43. 2002
    ..We conclude that the extended low-dose schedule of temozolomide is well tolerated in heavily pre-treated patients; however, our results do not support an improved rate of response or survival...
  26. ncbi request reprint Systemic high-dose intravenous methotrexate for central nervous system metastases
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 78:255-60. 2006
    ..Rapid infusion of high-dose intravenous methotrexate (HD IV MTX) penetrates the blood-brain barrier (BBB) and has reported activity in leptomeningeal metastases...
  27. ncbi request reprint International study on low-grade primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Neurol 59:755-62. 2006
    ..The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma...
  28. ncbi request reprint Isolated primary intracerebral mycetoma: presenting as a mass lesion in a patient with prostate cancer and multiple myeloma
    Shyam Prabhakaran
    Department of Neurology and Neuroscience, New York Presbyterian Hospital Weill Medical Center of Cornell University, USA
    J Neurooncol 71:49-52. 2005
    ..A brief review of the literature discusses the rarity, presentation, diagnosis, and management of primary intracerebral mycetomas...
  29. ncbi request reprint Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
    ....
  30. ncbi request reprint Chordoid glioma: report of a case with unusual histologic features, ultrastructural study and review of the literature
    Jeffrey J Raizer
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 63:39-47. 2003
    ..Treatment and long term outcome are limited but chordoid gliomas appear to be indolent lesions that may be cured with gross total resection...
  31. ncbi request reprint High-grade gliomas in patients with prior systemic malignancies
    Fernando C Maluf
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 94:3219-24. 2002
    ..The current study was conducted to characterize the impact of a prior malignancy on the diagnosis, treatment, and outcome of high-grade glioma...